Worldwide microbiome drugs market is likely to grow substantially by 2022

The most positive factor for these drugs is that they do not have any adverse effects since they are already present in the body. Therefore, several small and big companies are exploring its benefits on many diseases such as Crohn’s disease, oral biofilm, and irritable bowel syndrome, which usually does not have a specific course of treatment.

The use of microbiomes in dietary supplements can result in a positive outlook for the market. In microbiome therapeutics, probiotics and prebiotics play a crucial role in prevention, diagnosis, and treatment of several ailments. Factors such as growing research and development (R&D) activities, huge number of pipeline drugs, increasing adoption among individuals, and rising occurrence of obesity, diabetes, cancer, gastrointestinal diseases, mental disorders, and autoimmune diseases can propel the market during the forecast period (2017 to 2022).

Download free request sample @

Additionally, increasing governments initiatives, technological progression, and mounting association between pharmaceutical companies for new drug development can drive the market in the future. However, lack of awareness regarding the use of microbiome drugs may restrain market growth over the forecast period.

The worldwide microbiome drugs market can be fragmented on the basis of type and end users/application. Based on type, the market can be categorized into probiotics, prebiotics, small molecules, biological drugs, and others. As per end users/application, the market can be classified into hospital pharmacies, retail pharmacies, online pharmacies, and others.

Geographically, the microbiome drugs market can be divided into United States, Southeast Asia, Europe, Japan, China and, India. United States represents one of the largest markets owing to growing consumption of dietary supplements in the region. Factors such as growing awareness, high healthcare expenditure, and availability of advanced infrastructure and facilities for making microbiome products can drive the demand in the region.

Europe is considered as the second largest market due to increasing number of R&D activities and existence of a large number of biotechnology firms. Southeast Asia microbiome drugs market is predicted to grow at a high growth rate. This growth can be attributed to increasing awareness among the people, rising disposable income, existence of high target patients, soaring occurrence of diabetes, and growing government support.

Prominent companies operating in the microbiome drugs market include MicroBiome Therapeutics, Pfizer, Ritter Pharmaceuticals, Enterome Bioscience, and MaaT Pharma. Companies are investing a lot of money and effort in research and development activities for developing more effective products. Companies are also trying to create more opportunities in both developed as well as developing countries. Start-ups are enthusiastically working on numerous disease conditions for developing medicines from the microbiome technology platform. However, big companies are involved in inorganic growth by collaborating or purchasing licenses.

View full report here @

Increasing collaboration between pharmaceutical companies for new drug development is also expected to drive microbiome drugs market growth. Recently, Vedanta Biosciences announced that it has sub-licensed an important intelligent property from JSR Corporation for developing and commercializing microbiome-derived cancer immunotherapies, which is based on live biotherapeutics. These live biotherapeutics are likely to activate a type of white blood cell called CD8+ T cells.

Herbalife, a nutrition company, recently introduced Simply Probiotic, an easy to use powdered probiotic. It offers around one billion active probiotic cultures per serving. This powdered probiotic is portable and can be preserved at room temperature. It can be easily mixed with cold, hot, or frozen food and is considered useful for gut balance.

Media Contact
Company Name: Radiant Insights, Inc.
Contact Person: Michelle Thoras, Corporate Sales Specialist – USA
Phone: (415) 349-0054, Toll Free: 1-888-928-9744
Address:201 Spear Street 1100, Suite 3036
City: San Francisco
State: California
Country: United States